Biotech · Private company · Framingham, MA, US
KalVista Pharmaceuticals, Inc.
SEC CIK 0001348911
Track this companyFree. Adds KalVista Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials111 recruiting or active
Pipeline programs10From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline10
- Drug: KVD900 300 mgPhase 3 · Hereditary AngioedemaClinicalTrials.gov · fetched Nov 12, 2026
- KVD900 150 mgPhase 3 · Hereditary AngioedemaClinicalTrials.gov · fetched Nov 12, 2026
- KVD900 300 mgPhase 3 · Hereditary AngioedemaClinicalTrials.gov · fetched Nov 12, 2026
- KVD900 600 mgPhase 3 · Hereditary AngioedemaClinicalTrials.gov · fetched Nov 12, 2026
- KVD001 InjectionPhase 2 · Diabetic Macular EdemaClinicalTrials.gov · fetched Nov 12, 2026
- KVD824Phase 2 · Angioedema, Hereditary, Types I and IIClinicalTrials.gov · fetched Nov 12, 2026
- KVD900Phase 2 · Hereditary AngioedemaClinicalTrials.gov · fetched Nov 12, 2026
- Sham ProcedurePhase 2 · Diabetic Macular EdemaClinicalTrials.gov · fetched Nov 12, 2026
- InapplicableHereditary AngioedemaClinicalTrials.gov · fetched Nov 12, 2026
- SebetralstatHereditary AngioedemaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials11
- Safety and Effectiveness of Sebetralstat (KVD900) for Short-Term Prophylaxis Before Procedures in People With Hereditary Angioedema (KONTROL)PHASE4 · RECRUITING · started Aug 17, 2026ClinicalTrials.gov NCT07654829 · fetched Nov 12, 2026
- A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE AttacksCOMPLETED · started Apr 21, 2025ClinicalTrials.gov NCT07009262 · fetched Nov 12, 2026
- Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or IIPHASE3 · COMPLETED · started Aug 1, 2024ClinicalTrials.gov NCT06467084 · fetched Nov 12, 2026
- PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 TrialPHASE3 · COMPLETED · started Oct 24, 2022ClinicalTrials.gov NCT05511922 · fetched Nov 12, 2026
- An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)PHASE3 · COMPLETED · started Oct 24, 2022ClinicalTrials.gov NCT05505916 · fetched Nov 12, 2026
- A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)PHASE3 · COMPLETED · started Feb 22, 2022ClinicalTrials.gov NCT05259917 · fetched Nov 12, 2026
- A Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or IIPHASE2 · TERMINATED · started Nov 18, 2021ClinicalTrials.gov NCT05055258 · fetched Nov 12, 2026
- A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or IIPHASE2 · COMPLETED · started Jul 2, 2019ClinicalTrials.gov NCT04208412 · fetched Nov 12, 2026
- Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME)PHASE2 · COMPLETED · started Feb 16, 2018ClinicalTrials.gov NCT03466099 · fetched Nov 12, 2026
- Treatment of Angioedema Attacks in Adolescent and Adult Patients 12 Years and Older With HAE Type I or II With SebetralstatAPPROVED_FOR_MARKETINGClinicalTrials.gov NCT06628713 · fetched Nov 12, 2026
- Treatment of Angioedema Attacks in Pediatric (Ages 2-11) Post-Trial and Naive Patients With HAE With SebetralstatAVAILABLEClinicalTrials.gov NCT07216378 · fetched Nov 12, 2026
SEC filings12
- 8-K · FORM 8-KSEC EDGAR · filed Jun 11, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 14, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 29, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 25, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jan 8, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Nov 10, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 10, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 6, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 2, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 29, 2025 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Sep 11, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 11, 2025 · fetched Nov 12, 2026